[Interventional treatment in hypertrophic cardiomyopathy]

Area of Science:

• Cardiology
• Genetics
• Cardiac Electrophysiology

Context:

• Hypertrophic cardiomyopathy (HCM) affects approximately 0.2% of the population.
• Sudden death accounts for 50-80% of mortality in HCM patients, particularly younger individuals.
• Managing severe heart failure symptoms and preventing sudden cardiac death are key challenges in HCM care.

Purpose:

• To review current understanding of hypertrophic cardiomyopathy (HCM).
• To outline risk factors for sudden cardiac death in HCM patients.
• To discuss available treatment options for symptomatic HCM and sudden death prevention.

Summary:

• HCM is a genetic cardiac disease with significant mortality, primarily from sudden death.
• Risk stratification involves identifying markers like prior cardiac arrest, family history, and severe left ventricular hypertrophy.
• Treatment options include surgical myectomy, transcoronary ablation of septal hypertrophy (TASH), pacing, ablation, and implantable cardioverter-defibrillators (ICDs).

Impact:

• Effective management of HCM requires a comprehensive approach to both symptom control and sudden death prevention.
• Risk stratification guides prophylactic interventions, such as ICD implantation, for high-risk individuals.
• Further research, including randomized studies, is needed to fully elucidate the long-term efficacy and comparative benefits of various treatment modalities.